Molecular Biosystems' ultrasound agent enters trials in Japan:
This article was originally published in Clinica
Chugai Pharmaceuticals has begun clinical trials in Japan of Molecular Biosystems' (MBI) cardiac ultrasound imaging agent, Optison. MBI and Chugai entered a licensing agreement in April 1998 to develop and commercialise FS069 (the Japanese name for Optison) and another agent, Oralex. Japan is the world's second largest market for ultrasound imaging after the US.